Anti-Gal A/B, a novel anti-blood group antibody identified in recipients of ABO-incompatible kidney allografts

被引:27
作者
Galili, U
Ishida, H
Tanabe, K
Toma, H
机构
[1] Rush Univ, Dept Cardiovasc Thorac Surg, Chicago, IL 60612 USA
[2] Rush Univ, Dept Immunol, Chicago, IL 60612 USA
[3] Tokyo Womens Med Univ, Dept Urol, Tokyo, Japan
关键词
D O I
10.1097/00007890-200212150-00015
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The most prevalent anticarbohydrate antibodies in human serum are anti-Gal interacting specifically with the a-gal epitope (Galalpha1-3Galbeta1-4Gl-cNAc-R) and anti-blood group antibodies interacting with blood group A and B antigens. The a-gal epitope, although absent in humans, comprises part of the core of carbohydrate chain in A and B antigens. Therefore, it was of interest to determine whether immunoglobulin (Ig) G antibodies, elicited in patients rejecting ABO-incompatible kidney allografts, can interact with the a-gal epitope. Methods. Anti-A and anti-B antibodies were determined by enzyme-linked immunosorbent assay (ELISA) with blood group A or B human red cell membranes, as solid phase antigens. Anti-Gal was determined by ELISA with alpha-gal-bovine serum albumin as solid-phase antigen. Specific removal of anti-Gal was performed by adsorption on fixed rabbit red cells. Results. Blood group O patients who underwent transplantation with either A or B kidney produced an antibody that bound to all three carbohydrate antigens. This multispecific antibody, designated anti-Gal A/B, is specific to the core alpha-gal epitope within A and B antigens. Recipients of allograft expressing incompatible blood group B also produce anti-Gal B antibody, which binds to the core a-gal epitope only in the B antigen. Anti-Gal A/B and anti-Gal B constitute most of the elicited anti-blood group antibody response. Allograft recipients also produced pure anti-A, or pure anti-B, which require the complete blood group structure for binding. Conclusions. The findings in this study imply that much of the immune response elicited by incompatible A or B antigens on kidney allografts results in activation of anti-Gal B-cell clones producing antibodies to the core a-gal epitope in these blood group antigens. Only less than 25% of the elicited antibodies interact with the complete A or B antigens (i.e., pure anti-A or pure anti-B). These findings suggest that prevention of the anti-Gal response may decrease the immune rejection of ABO-incompatible allografts.
引用
收藏
页码:1574 / 1580
页数:7
相关论文
共 26 条
[1]  
ALEXANDRE GPJ, 1987, TRANSPLANT P, V19, P4538
[2]  
BANNETT AD, 1987, TRANSPLANT P, V19, P4543
[3]  
COLLINS BH, 1995, J IMMUNOL, V154, P5500
[4]   ONE PERCENT OF HUMAN CIRCULATING B-LYMPHOCYTES ARE CAPABLE OF PRODUCING THE NATURAL ANTI-GAL ANTIBODY [J].
GALILI, U ;
ANARAKI, F ;
THALL, A ;
HILLBLACK, C ;
RADIC, M .
BLOOD, 1993, 82 (08) :2485-2493
[5]   THE HUMAN NATURAL ANTI-GAL IGG .3. THE SUBTLETY OF IMMUNE TOLERANCE IN MAN AS DEMONSTRATED BY CROSS-REACTIVITY BETWEEN NATURAL ANTI-GAL AND ANTI-B ANTIBODIES [J].
GALILI, U ;
BUEHLER, J ;
SHOHET, SB ;
MACHER, BA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1987, 165 (03) :693-704
[6]  
GALILI U, 1988, J BIOL CHEM, V263, P17755
[7]   A UNIQUE NATURAL HUMAN-IGG ANTIBODY WITH ANTI-ALPHA-GALACTOSYL SPECIFICITY [J].
GALILI, U ;
RACHMILEWITZ, EA ;
PELEG, A ;
FLECHNER, I .
JOURNAL OF EXPERIMENTAL MEDICINE, 1984, 160 (05) :1519-1531
[8]   HUMAN NATURAL ANTI-ALPHA-GALACTOSYL IGG .2. THE SPECIFIC RECOGNITION OF ALPHA-(1 -] 3)-LINKED GALACTOSE RESIDUES [J].
GALILI, U ;
MACHER, BA ;
BUEHLER, J ;
SHOHET, SB .
JOURNAL OF EXPERIMENTAL MEDICINE, 1985, 162 (02) :573-582
[9]   EVOLUTIONARY RELATIONSHIP BETWEEN THE NATURAL ANTI-GAL ANTIBODY AND THE GAL-ALPHA-1-]3GAL EPITOPE IN PRIMATES [J].
GALILI, U ;
CLARK, MR ;
SHOHET, SB ;
BUEHLER, J ;
MACHER, BA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (05) :1369-1373
[10]   INTERACTION OF THE NATURAL ANTI-GAL ANTIBODY WITH ALPHA-GALACTOSYL EPITOPES - A MAJOR OBSTACLE FOR XENOTRANSPLANTATION IN HUMANS [J].
GALILI, U .
IMMUNOLOGY TODAY, 1993, 14 (10) :480-482